Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on … [Read more…]
Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.–(BUSINESS WIRE)–#BKV–Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause … [Read more…]
$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for … [Read more…]
52-week Phase 3 trial evaluating the efficacy and safety of sonlicromanol, a novel brain-penetrant redox-modulator with anti-ferroptotic and anti-inflammatory properties, in adult patients with the most common genetic defect causing primary mitochondrial disease, m.3243A>G Primary endpoints focus on most bothersome and frequently occurring effects of disease – chronic fatigue and muscle weakness – supported by … [Read more…]
AURORA, Ill.–(BUSINESS WIRE)–Simplify Healthcare®, a Simplify Group™ company and a leading organization in the healthcare payer technology space, today announced a strategic alliance with Sagility and Convey Health Solutions (Convey) to launch Sagility Synchrony, a purpose-built, end-to-end Medicare Advantage lifecycle solution. Sagility Synchrony replaces fragmented point solutions with a Sagility-led, end-to-end managed services model powered … [Read more…]
Better Care Services platform connects customers to virtual care and nutrition support, complementing fast, convenient access to medications through Walmart’s nationwide pharmacy network BENTONVILLE, Ark.–(BUSINESS WIRE)–As more customers seek support for weight management and overall health, Walmart is expanding its Better Care Services platform with new offerings that bring together virtual care, nutrition services and … [Read more…]
Condition-specific lab packages starting at $50 give providers the tools to compete with self-service health subscriptions OTTAWA, Ontario–(BUSINESS WIRE)–Fullscript, a provider-led health platform doing over $1B in revenue annually, used by more than 125,000 healthcare providers and more than 5 million patients annually across North America, today announced the general availability of Fullscript Journeys, a … [Read more…]
MONTREAL–(BUSINESS WIRE)–“This research project, benefiting from a budget of $2.2 million, one of six jointly supported by Genome Canada and Génome Québec, aims to set up a high-throughput platform integrating genetic transformation, multi-omics analyses, and phenotype detection through hyperspectral imaging, using artificial intelligence, allowing for accelerated selection of clonal plant lines,” says Dr. Davoud Torkamaneh, … [Read more…]
SYDNEY–(BUSINESS WIRE)–#ArtificialIntelligence–Integrant, a pioneering Australian biotechnology company, proudly announced today that it has officially been granted the Nasdaq ticker symbol **INGT**. This milestone facilitates the company’s highly anticipated Initial Public Offering (IPO) on the Nasdaq Stock Market, positioning Integrant as a global leader in AI-enhanced regenerative medicine. Established in Sydney, Integrant specialises in the seamless … [Read more…]
VANCOUVER, British Columbia & GRAPEVINE, Texas–(BUSINESS WIRE)–Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to … [Read more…]
